Venezuelan Generics Law Draft Queried

11 November 1996

Draft pharmaceutical legislation which is aimed at promoting the development of generic drug products in Venezuela has been brought into question by Procompetencia, the country's organization for the promotion of free competition.

The law's basic intention is to guarantee access and availability of pharmaceuticals to the entire Venezuelan population by means of a system of control over the generics sector, according to Procompetencia. However, it adds, the situation is less clear than it appears, because the guarantee would depend on the maintenance of supervision over all phases of production, and the maintenance of health norms.

Moreover, the organization points out that while the government envisages dividing generics production between the 200 or so drugmakers operating in the country, the new law would not oblige any of them to produce generics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight